Article Information
History
- September 17, 2022.
Article Versions
- You are currently viewing Version 1 of this article (September 17, 2022 - 11:03).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ana Beatriz Cazé Cerón1,
- Thiago Cerqueira-Silva, MD1,2,
- Adriele Pinheiro Bomfim, M. Sc.3,1,
- Gisley Lima de Souza4,5,
- Amanda Canário Andrade Azevedo, MD, M.Sc.6,
- Michelle Queiroz Aguiar Brasil, MD, M. Sc.5,7,
- Nara Rúbia Santos8,
- Antônio Ricardo Khouri Cunha, PhD9,5,
- Jennifer Dan, MD, PhD10,11,
- Antonio Carlos Bandeira, MD, PhD, Infectious Diseases Advisor12,13,
- Luciano Pamplona de Goes Cavalcanti, MD, PhD14,15,
- Manoel Barral-Netto, MD, PhD2,1,
- Aldina Maria Prado Barral16,17,
- Cynara Gomes Barbosa, PhD*,18 and
- Viviane Sampaio Boaventura de Oliveira, MD, PhD*,2,1,†
- 1Universidade Federal da Bahia, Salvador, Bahia, Brazil
- 2LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
- 3Instituto Gonçalo Muniz, Fiocruz, Salvador, Brazil
- 4Escola de Medicina e Saúde Pública da Bahia
- 5Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
- 6Hospital Santa Izabel, Santa Casa da Bahia, Salvador, Bahia, Brazil
- 7Federal University of Bahia, Salvador, Bahia, Brazil
- 8Departamento de Vigilância em Saúde/Vigilância Epidemiológica, Campo Formoso, Bahia Brazil
- 9Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Clinical and Epidemiological Virology, Belgium
- 10Center for Infectious Disease and Vaccine Research, la Jolla Institute for Immunology (LJI)
- 11Department of Medicine, Division of Infectious Disease and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA
- 12UNI-FTC-Faculdade Tecnologia Ciências Medical School, Bahia
- 13Central State Laboratory LACEN-Bahia
- 14Universidade Federal do Ceará, Fortaleza, Ceará, Brazil
- 15Centro Universitario Christus, Fortaleza, Ceará, Brazil
- 16Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil
- 17Instituto de Investigação em Imunologia, São Paulo, São Paulo, Brazil
- 18Universidade Federal da Bahia, Salvador, Brazil
- ↵†Corresponding author
Viviane Sampaio Boaventura, Email address: vsboaventura{at}gmail.com, Telephone: + 55 71 31762211, Postal address: 121 Waldemar Falcão Street, Candeal, Salvador, Bahia, Brazil, CEP 40296
↵* Those authors equally supervised this study
Posted September 17, 2022.
Prevalence and risk factors for long COVID after mild disease: a longitudinal study with a symptomatic control group
